Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Starpharma Holdings Limited ( (AU:SPL) ) is now available.
Starpharma Holdings Limited has applied to the ASX for quotation of 1,012,747 new fully paid ordinary shares under the code SPL, issued on 11 March 2026 following the exercise or conversion of existing options or other convertible securities. The additional quoted securities modestly increase the company’s share capital and free float, with implications for shareholder dilution and trading liquidity once admitted to quotation.
The move signals ongoing utilisation of equity-linked incentives or financing structures within Starpharma’s capital management framework, reflecting continued engagement from holders of options or convertibles. For investors, the change represents a routine but notable adjustment to the company’s capital base and may slightly influence market dynamics around SPL’s stock as the new shares commence trading.
The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.46 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.
More about Starpharma Holdings Limited
Starpharma Holdings Limited is an Australian-listed biotechnology company focused on developing pharmaceutical products, leveraging advanced technologies to create therapeutics and related healthcare solutions. Its shares trade on the ASX under the ticker SPL, giving investors exposure to the life sciences and biotech sector.
YTD Price Performance: 38.89%
Average Trading Volume: 1,368,619
Technical Sentiment Signal: Hold
Current Market Cap: A$210M
See more data about SPL stock on TipRanks’ Stock Analysis page.